Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised Phase 2 Monotherapy Trial of Bemcentinib in the later line elderly Patients with Acute-Myeloid-Leukaemia

Trial Profile

A Randomised Phase 2 Monotherapy Trial of Bemcentinib in the later line elderly Patients with Acute-Myeloid-Leukaemia

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bemcentinib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors BerGenBio
  • Most Recent Events

    • 01 Apr 2019 According to a BerGenBio media release, the Company is proceeding with preparations for this late-stage bemcentinib monotherapy trial in acute myeloid leukaemia.This study is expected to start in the second half of 2019 and will aim to confirm previously reported monotherapy efficacy of bemcentinib in AML patients whose disease has progressed on standard of care therapy.
    • 05 Dec 2018 New trial record
    • 26 Nov 2018 According to a BerGenBio media release, this trial is expected to begin in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top